EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,168 | +14.3% | 99,204 | 0.0% | 0.04% | +5.3% |
| Q2 2023 | $1,896 | -1.6% | 99,204 | 0.0% | 0.04% | -7.3% |
| Q1 2023 | $1,926 | +21.1% | 99,204 | 0.0% | 0.04% | +13.9% |
| Q4 2022 | $1,591 | -99.9% | 99,204 | 0.0% | 0.04% | -5.3% |
| Q3 2022 | $1,556,000 | -10.7% | 99,204 | +18.5% | 0.04% | -7.3% |
| Q2 2022 | $1,743,000 | +54.9% | 83,734 | +68.7% | 0.04% | +24.2% |
| Q1 2022 | $1,125,000 | +24.0% | 49,626 | 0.0% | 0.03% | +32.0% |
| Q4 2021 | $907,000 | +15.4% | 49,626 | +33.5% | 0.02% | -13.8% |
| Q3 2021 | $786,000 | +16.1% | 37,170 | 0.0% | 0.03% | +3.6% |
| Q2 2021 | $677,000 | -19.4% | 37,170 | 0.0% | 0.03% | -24.3% |
| Q1 2021 | $840,000 | +12.6% | 37,170 | 0.0% | 0.04% | +5.7% |
| Q4 2020 | $746,000 | +48.0% | 37,170 | +80.3% | 0.04% | -47.8% |
| Q3 2020 | $504,000 | – | 20,617 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |